Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.36 |
| ▸ | METTL14 | Q9HCE5 | 2/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19803225 | 0.93 | THRB (0.44) | THRBFEN1ALOX5APSLC6A9EGFR | |
| SCHEMBL19804605 | 0.89 | THRB (0.43) | THRBFEN1ALOX5APSLC6A9METTL3 | |
| SCHEMBL19804419 | 0.88 | THRB (0.45) | THRBSLC6A9EGFRLTB4RLTB4R2 | |
| SCHEMBL19804096 | 0.87 | CTSA (0.38) | THRBFEN1ALOX5APLTB4RLTB4R2 | |
| SCHEMBL19796721 | 0.86 | RARB (0.47) | THRB | |
| SCHEMBL19804480 | 0.86 | THRB (0.40) | THRBFEN1ALOX5APSLC6A9FFAR1 | |
| SCHEMBL19804546 | 0.85 | ALOX5AP (0.43) | THRBFEN1ALOX5APSLC6A9EGFR | |
| SCHEMBL19804344 | 0.85 | ALOX5AP (0.39) | FEN1ALOX5APSLC6A9EGFRLTB4R | |
| SCHEMBL19796287 | 0.84 | THRB (0.39) | THRBLTB4RLTB4R2 | |
| SCHEMBL19804724 | 0.84 | CYP3A4 (0.46) | THRBFEN1ALOX5APSLC6A9FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | THRB 4323/4885FEN1 2669/4885ALOX5AP 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.